Want to see TSE:BUX full AI Analyst Report?
Top Page
BioMark Diagnostics
(BUX)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.53
▲(5.60% Upside)
Action:Reiterated
Date:09/06/26
The score is driven primarily by weak financial performance: steep TTM revenue decline, persistent large losses, and ongoing cash burn alongside elevated leverage. Technicals add further pressure with a bearish trend (price below key moving averages and negative MACD), though oversold RSI/Stoch slightly temper the outlook. Valuation provides limited support because the negative P/E reflects loss-making operations and no dividend yield is available.
Positive Factors
Early-detection focus
A focused blood-based early-detection platform addresses an important clinical need and gives the company a defined strategic direction. If development and validation progress, this specialization could support differentiated diagnostic applications across cancer and other diseases over the medium term.
Negative Factors
Revenue and margin deterioration
Sharp revenue contraction combined with negative gross profit shows that the current operating model is not yet producing adequate scale or sustainable unit economics. Persistent deterioration weakens funding capacity and makes future product development increasingly dependent on external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Early-detection focus
A focused blood-based early-detection platform addresses an important clinical need and gives the company a defined strategic direction. If development and validation progress, this specialization could support differentiated diagnostic applications across cancer and other diseases over the medium term.
Read all positive factors
BioMark Diagnostics (BUX) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$59.63M
Dividend YieldN/A
Average Volume (3M)5.60K
Price to Earnings (P/E)―
Beta (1Y)0.17
Revenue Growth-82.05%
EPS Growth23.73%
CountryCA
Employees9
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.01
Shares Outstanding106,483,440
10 Day Avg. Volume5,449
30 Day Avg. Volume5,598
Financial Highlights & Ratios
PEG Ratio1.07
Price to Book (P/B)180.94
Price to Sales (P/S)1001.91
P/FCF Ratio-54.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BioMark Diagnostics Business Overview & Revenue Model
Company Description
BioMark Diagnostics Inc. is an oncology specialist, developing advanced diagnostic tools for cancer to enable early detection, continuous patient monitoring, and the assessment of initial treatment efficacy. The firm holds a research partnership w...
BioMark Diagnostics Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
28
Negative
Cash Flow
12
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 59.79K | 154.22K | 163.22K | 153.49K | 0.00 |
| Gross Profit | -322.49K | 154.22K | 163.22K | -232.70K | -13.69K |
| EBITDA | -1.49M | -1.46M | -919.05K | -1.35M | -1.08M |
| Net Income | -1.48M | -1.93M | -1.43M | -1.84M | -1.09M |
Balance Sheet | |||||
| Total Assets | 1.86M | 3.13M | 1.09M | 732.29K | 952.94K |
| Cash, Cash Equivalents and Short-Term Investments | 1.01M | 2.48M | 156.75K | 72.04K | 877.68K |
| Total Debt | 724.86K | 454.16K | 1.55M | 823.87K | 119.32K |
| Total Liabilities | 1.53M | 1.39M | 1.70M | 1.88M | 1.03M |
| Stockholders Equity | 331.06K | 1.74M | -609.61K | -1.15M | -79.09K |
Cash Flow | |||||
| Free Cash Flow | -1.09M | -1.10M | -986.91K | -919.72K | -455.55K |
| Operating Cash Flow | -1.09M | -1.09M | -982.52K | -914.42K | -455.55K |
| Investing Cash Flow | -396.05K | -3.53K | -4.39K | -5.30K | -3.20K |
| Financing Cash Flow | -377.83K | 3.42M | 1.07M | 609.05K | 724.63K |
BioMark Diagnostics Technical Analysis
Positive
0.50
Price Trends
0.53
Positive
0.55
Positive
0.54
Positive
Market Momentum
0.01
Negative
63.81
Neutral
90.48
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BUX, the sentiment is Positive. The current price of 0.5 is below the 20-day moving average (MA) of 0.51, below the 50-day MA of 0.53, and below the 200-day MA of 0.54, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 63.81 is Neutral, neither overbought nor oversold. The STOCH value of 90.48 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BUX.
BioMark Diagnostics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | C$6.03M | -2.36 | 902.36% | ― | ― | 26.96% | |
43 Neutral | C$40.52M | -15.19 | 448.05% | ― | ― | 24.65% | |
42 Neutral | C$59.63M | -40.74 | -250.77% | ― | -82.05% | 23.73% | |
41 Neutral | C$346.20M | -8.63 | 51.23% | 47.06% | 1.46% | -64.85% |
* Healthcare Sector Average
TSE:BUX
BioMark Diagnostics
0.55
0.19
52.78%
TSE:EDT
Spectral Medical
1.11
-0.33
-22.92%
TSE:TELO
Telo Genomics Corp
0.06
>-0.01
-8.33%
TSE:SZLS.H
StageZero Life Sciences Ltd
0.04
0.00
0.00%
TSE:ZYUS
ZYUS Life Sciences
0.60
-0.10
-14.29%
TSE:SONA
Sona Nanotech Inc
0.33
-0.30
-47.58%
BioMark Diagnostics Corporate Events
Business Operations and StrategyProduct-Related Announcements
BioMark to Spotlight Metabolomics Platform at Quebec Life Sciences Conferences
Positive
Sep 21, 2026
BioMark Diagnostics will participate in the MSACL 2026 and BIOHorizon 2026 conferences in Quebec in early October, engaging clinical mass spectrometry experts, decision-makers, and investors. The company plans to highlight its metabolomics-based l...
Business Operations and Strategy
BioMark Wins Global Scientific Backing for AI-Driven Lung Cancer Blood Test
Positive
Aug 25, 2026
BioMark Diagnostics has reported significant scientific momentum for its metabolomics-based liquid biopsy platform for early lung cancer detection, with five peer-reviewed studies published in the past nine months. The company’s blood-based ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.